NewEdge Advisors’s Zymeworks ZYME Stock Holding History

NewEdge Advisors’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100	Closed	-$786	–	4201
2022 Q4	$786	Buy	+100	New	+$703	﹤0.01%	3093

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

NewEdge Advisors's ZYME Position: Q1 2023 in Review

NewEdge Advisors sold out of Zymeworks (ZYME) in Q1 2023, closing a stake of 100 shares — an estimated $786 sold.

NewEdge Advisors first reported a position in ZYME in Q4 2022 and held it in 1 quarter. The position peaked at $786 in Q4 2022. 115 funds tracked by Wall St. Rank hold ZYME as of Q1 2023.

NewEdge Advisors reported no remaining Zymeworks position as of Q1 2023 after selling out during the quarter.
NewEdge Advisors sold 100 Zymeworks shares in Q1 2023, an estimated $786.
NewEdge Advisors first reported a position in Zymeworks in Q4 2022 and held it in 1 quarter.
NewEdge Advisors's Zymeworks position peaked at $786 in Q4 2022.
115 funds tracked by Wall St. Rank held Zymeworks as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.